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Toronto, Toronto, Ontario, CanadaA B S T R A C TBackground: Biologic therapies are considered the standard of care
for children with the most severe forms of juvenile idiopathic arthritis
(JIA). Inconsistent and inadequate drug coverage, however, prevents
many children from receiving timely and equitable access to the best
treatment. Objective: The objective of this study was to evaluate
parents’willingness to pay (WTP) for biologic and nonbiologic disease-
modifying antirheumatic drugs (DMARDs) used to treat JIA. Methods:
Utility weights from a discrete choice experiment were used to
estimate the WTP for treatment characteristics including child-
reported pain, participation in daily activities, side effects, days
missed from school, drug treatment, and cost. Conditional logit
regression was used to estimate utilities for each attribute level, and
expected compensating variation was used to estimate the WTP.
Bootstrapping was used to generate 95% conﬁdence intervals for all
WTP estimates. Results: Parents had the highest marginal WTP for
improved participation in daily activities and pain relief followed byee front matter Copyright & 2014, International S
r Inc.
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ing, 11th Floor, 686 Bay Street, Toronto, ON, Canathe elimination of side effects of treatment. Parents were willing to
pay $2080 (95% conﬁdence interval $698–$4065) more for biologic
DMARDs than for nonbiologic DMARDs if the biologic DMARD
was more effective. Conclusions: Parents’ WTP indicates their
preference for treatments that reduce pain and improve daily
functioning without side effects by estimating the monetary equiv-
alent of utility for drug treatments in JIA. In addition to evidence
of safety and efﬁcacy, assessments of parents’ preferences provide
a broader perspective to decision makers by helping them under-
stand the aspects of drug treatments in JIA that are most valued by
families.
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arthritis, willingness to pay.
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Juvenile idiopathic arthritis (JIA) is a debilitating disease that
affects approximately 1 in 1000 children in North America [1].
Active JIA causes pain and stiffness, which limits a child’s ability
to participate in normal daily activities. When left untreated, it
can lead to permanent joint damage and disability that will carry
forward into adulthood [2,3]. For patients with the most severe
forms of JIA, conventional treatments including nonbiologic
disease-modifying antirheumatic drugs (DMARDs) are often not
adequate to control clinical symptoms [4]. In these cases, biologic
DMARDs have been shown to effectively improve symptoms and
health-related quality of life [4,5]. International JIA treatment
guidelines recommend biologic therapies as the standard of care
for patients refractory to nonbiologic DMARDs [6]. Unfortunately,uptake of these recommendations is impeded by inconsistent
and, in some cases, inadequate drug reimbursement programs
[7–9].
Access to drug treatments in JIA has been recognized as an
important policy issue across North America and Europe [9–11].
Biologic therapies are more expensive than nonbiologic thera-
pies, costing approximately CAN $16,000 to CAN $19,000 per year
($1,333–$1,553 per month) for a single child with JIA, compared
with CAN $950 ($79 per month) for methotrexate (2008 annual
average CAN $1 ¼ US $0.938) [12]. Value for money in terms of
health beneﬁts and costs is therefore an important consideration
in drug plan decisions regarding which drugs to cover. Coverage
of these drugs for pediatric use is highly variable in public plans
across Canada, and in Ontario requires a special request through
an exceptional access mechanism [13].ociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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inform coverage decisions is often based on the framework of health
technology assessment (HTA), which takes into account the com-
parative effectiveness, safety, cost-effectiveness, and social, legal,
and ethical aspects of the new drug, including information on public
and patient preferences [14]. Preferences are most useful to decision
makers when they are derived from scientiﬁcally rigorous methods
that allow for quantiﬁcation in the form of utilities or willingness to
pay (WTP) [15]. Discrete choice experiments (DCEs) offer a ﬂexible
and theoretically grounded approach to estimating theWTP [16] and
have been used in a growing number of studies to value preferences
for a wide range of treatments, services, and health outcomes in
children and newborns [17–19]. DCEs ask subjects to make trade-offs
between scenarios that vary in a number of characteristics, which
can include cost. They are designed to resemble the types of
decisions people make in the real world, in which money is traded
to obtain a scenario with the most desirable characteristics [20].
Improving outcomes in JIA depends on the availability of safe
and effective treatments, which for many patients include bio-
logic therapies. Unfortunately, little is known about the value for
money of these drugs from the perspective of patients’ families.
The objective of this study was to conduct a DCE to determine the
aspects of treatments that parents value the most and to
measure parents’ WTP for treatment proﬁles representing non-
biologic and biologic drugs.Methods
The study was approved by the Research Ethics Board at The
Hospital for Sick Children (Sick Kids), Toronto, Canada, and
participants provided informed consent.
Study Subjects and Recruitment
Eligible study subjects were identiﬁed from health records and the
Sick Kids Rheumatology Clinic database. Eligible subjects included
all parents of children with JIA who attended a clinic between June
2009 and June 2010 and had been prescribed a drug treatment for
JIA between June 2007 and June 2010. Non–English-speaking
parents and those caring for a patient with JIA with a signiﬁcant
comorbidity were excluded. Eligible study subjects had the option
to complete an online or mailed version of the survey. One month
after recruitment, they were telephoned and reminded of the study
every 2 weeks for 2 months. The survey booklet included the DCE
instrument and brief health and demographic questionnaires.
DCE Survey
The choice of attribute levels, development of the DCE instrument,
and pilot testing have been described previously [21]. Feedback from
a pilot study was incorporated into the ﬁnal instrument. Respond-
ents were asked to choose their preferred treatment scenario from a
series of two scenarios labeled A and B. This patient population
experiences extensive morbidity and treatment options are highly
variable depending on the patient’s clinical subtype and disease
severity. Including no treatment or status quo opt-out options was
therefore deemed unreasonable from clinical and ethical stand-
points. The attributes and levels evaluated were as follows: “child-
reported pain from arthritis” (none, mild, moderate, severe); “par-
ticipation in daily activities” (without any difﬁculty, with some
difﬁculty, with much difﬁculty, unable to participate); “side effects”
(none, headache 4 days per month, stomach pain 4 days per month,
nausea 4 days per month); “days missed from school” (0.5 days per
month, 1 day per month, 2 days per month, 4 days per month);
“drug treatment” (pill 4 days per month, injection 4 days per month,
intravenous [IV] infusion 1 day per month); and “cost to you” ($50
per month, $700 per month, $1500 per month, $2100 per month).The SAS MktEx macro [22] was used to generate the choice
experiment, which consisted of three questionnaire versions
each consisting of 16 choice sets. Field testing demonstrated
the feasibility of the number of choice tasks, and it was assumed
that respondents considered all the attributes and made a choice
that maximized utility. Some studies include repeat tasks to test
for logical or consistent choice selection. It remains unclear how
to handle inconsistent responders who simply may possess
unique decision-making heuristics [23,24]. Decision-making heu-
ristics in DCEs have been shown to be inﬂuenced by a number of
factors including the design of the experiment, framing of choice
questions, and appropriateness of attributes and levels. For these
reasons, and to reduce further burden, tests for rationality and
dominance were not included.
The time horizon for each choice set was 1 month, and all
attribute levels were framed within this period (e.g., headache 4 days
per month, cost $1500 per month). Because most parents face
medication cost sharing in the form of co-payments or the full cost
of medications for those without drug insurance, the inclusion of a
cost to you attribute was considered feasible and proved acceptable
through pilot testing. A statement explaining that “people often tend
to overstate how much they are willing to pay for hypothetical
treatments,” cautioning respondents to “carefully consider the cost
characteristic and respond as if you would actually have to pay the
extra amount each month,”was included in the survey instructions.
Such “cheap talk” scripts have been shown to provide more accurate
valuations of cost when included as an attribute in a DCE [25].
Data Analysis
Data analysis was carried out using SAS (version 9.2). Conditional
logit regression was used to analyze the effect of the attribute
levels on parents’ preferences [26]. All DCE attributes were included
in the regression model. Effects coding was used to describe the
categorical attributes and to derive parameter estimates for all
levels of all categorical attributes [27]. The attributes “days missed
from school” and “cost to you” were coded as continuous variables.
A test for linearity of the cost attribute was conducted by compar-
ing the regression coefﬁcients of “cost to you” coded as a contin-
uous variable to a categorical variable. Regression coefﬁcients for
each attribute level represent the overall utility for that parameter
according to the respondent sample. Standard errors of parameter
estimates from the conditional logit model represent robust clus-
tered errors (sometimes referred to as Huber-White or sandwich
errors). Demographic variables were also included in the model.
Interactions between demographic variables and attribute levels
displaying a P value of 0.05 or less were considered to have a
statistically signiﬁcant effect on preference. Model ﬁt was assessed
using McFadden’s pseudo R2 statistic [28]. Bootstrapping was used
to generate standard errors and 95% conﬁdence intervals (CIs) for
all parameter estimates. Bootstrapping involved sampling data
with replacement from the original data set, thus generating 1000
bootstrapped samples with 105 individuals per data set.
Willingness to Pay
The WTP was estimated using regression coefﬁcients from the
conditional logit model. Marginal WTP (MWTP) represented the
monetary equivalent of the change in parents’ utility for moving
from one level to another within an attribute (from worst to best),
holding all other attribute levels constant [29]. The MWTP was
determined by calculating the marginal rate of substitution: the
difference in utility between two levels within a single attribute
divided by the negative utility of cost.
The difference in the WTP for proﬁles resembling nonbiologic
and biologic DMARDs was estimated using expected compensat-
ing variation: the sum of utilities for one attribute level in a
Table 1 – Deﬁnitions of proﬁles used to represent nonbiologic and biologic DMARDs.
Attribute Nonbiologic Biologic
Injection Intravenous
Child-reported pain from arthritis Mild None None
Participation in daily activities With some difﬁculty Without any difﬁculty Without any difﬁculty
Side effects Nausea 4 days per month None None
Drug treatment Pill 4 times per month Injection 4 times per month Intravenous once per month
Days missed from school 1 day per month 0.5 days per month 1 day per month
Cost to you (per month) $50 $2100 $2100
DMARDs, disease-modifying anti-rheumatic drugs.
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proﬁles resembling a child responding inadequately to a non-
biologic DMARD and adequately to a biologic DMARD were
generated based on outcomes reported in the literature [4]. It
was assumed that a child responding inadequately to nonbiologic
therapy would report mild pain [30,31], experience some difﬁculty
participating in daily activities [31,32], suffer from nausea 4 days per
month [31,33], and miss 1 day of school per month [2,34].
A child responding adequately to biologic therapy was assumed to
report no pain [4,30], experience no difﬁculty participating in daily
activities [4,32], suffer from no side effects [4,33], and miss half a day
of school per month for injections or a full day for IV infusions
[2,4,34]. The route and frequency of administrations as well as costs
for each scenario represented standard clinical practice [33,35] and
the typical acquisition costs of each therapy in Ontario, Canada [12].
The base-case proﬁles are summarized in Table 1. One-way sensi-
tivity analyses were carried out by varying the levels of pain,
participation in daily activities, side effects, and drug treatment used
to represent a child on nonbiologic therapy. The sensitivity analyses
assumed that each attribute of interest used to represent the
nonbiologic therapy was equally effective to the biologic therapy
(e.g., no pain, no difﬁculty participating in daily activities, no side
effects, administered as an injection).
Bootstrapping was used to generate 95% CIs for all WTP
estimates [36]. Conditional logit analysis was then carried out
for each bootstrapped sample, and WTP values representing the
2.5th and 97.5th ranked values were used as the lower and upper
conﬁdence limits for each attribute.Table 2 – Summary of socioeconomic characteristics.
Characteristic n (%)
Annual household income ($)
High (480,000) 63 (60)
Middle (40,000–79,999) 17 (16)
Low (o39,999) 16 (15)
Unknown 9 (9)
Drug plans used to access drugs for JIA
Private insurance provided by employer 76 (73)
Private insurance purchased independently 4 (4)
Public drug program 11 (10)
None 14 (13)
Monthly out-of-pocket spending on drugs for JIA ($)
0 50 (48)
o50 29 (30)
50–200 16 (15)
250–500 5 (5)
41000 3 (3)
JIA, juvenile idiopathic arthritis.Results
Respondents
Of the parents who were mailed a study package (n ¼ 170), 62%
(n ¼ 105) responded, with 88% of the respondents choosing to
complete a hard copy. There was insufﬁcient data to determine
whether there were systematic differences between responders
and nonresponders. Most of the respondents were mothers (91%)
who had received a college or university degree (84%). The average
household size was 4.3  1.1 people, with 51% of the families
living in a large urban center (Toronto, Canada) and surrounding
areas. Approximately 62% of the parents were employed full time,
18% were employed part time, 13% were homemakers, and 6%
were unemployed or receiving government assistance. Household
incomes ranged from less than $20,000 per year to more than
$200,000 per year, with 19% of the families reporting in the highest
income bracket (4$200,000 per year). In terms of drug coverage,
72% had employer-provided private insurance and monthly out-
of-pocket spending on drugs for JIA ranged from $0 to $4000 per
month. Characteristics of respondents that relate to accessing
drug treatments in JIA can be found in Table 2.Preferences for Treatment Attributes
Results of the regression model are presented in Table 3. A total
of 1680 observations were derived from a sample of 105 respond-
ents. All attributes had a statistically signiﬁcant inﬂuence on
choice. The relative importance of attributes was as expected,
with parents showing the greatest preference for improved
“participation in daily activities” and reduced “child-reported
pain from arthritis”, followed by “cost,” “side effects”, and “drug
treatment”. “Days missed from school” was the attribute with the
smallest impact on parents’ preferences. A total of 11 signiﬁcant
interactions between demographic variables and treatment
attributes were identiﬁed. Household income and type of drug
coverage were the only variables found to interact signiﬁcantly
with the “cost to you” attribute. Parents from low- and middle-
income households were more sensitive to the cost attribute and
displayed a lower preference for out-of-pocket spending (“cost to
you” attribute) than did parents from high-income households.
Parents with public drug coverage demonstrated a stronger
preference for spending than did parents who had private cover-
age; however, this is based on only 11 respondents with public
coverage (10% of the sample).
Willingness to Pay
As described above, the MWTP represents a monetary equiva-
lence of utility for the transition from one level to another within
an attribute in the direction of improvement (e.g., from severe to
moderate pain) with all other attribute levels kept constant. In all
Table 3 – Parameter estimates from main effects and interactions from the conditional logit model of parents’
choice of A or B, and MWTP for treatment attributes.
Level Utility (95% CI) MWTP (95% CI) (CAN $) P
Child-reported pain from arthritis
None 0.995 (0.431 to 1.625) 744 (556 to 974) o0.0001
Mild 0.480 (0.046 to 0.950) 954 (882 to 1079) o0.0001
Moderate 0.181 (0.565 to 0.203) 1606 (855 to 2429) o0.0001
Severe† 1.294 (2.249 to 0.390) – –
Participation in daily activities
Without any difﬁculty 1.615 (1.024 to 2.431) 1484 (1173 to 2065) o0.0001
With some difﬁculty 0.587 (0.211 to 1.00) 1674 (1180 to 1807) o0.0001
With much difﬁculty 0.572 (1.041 to 0.182) 1528 (1108 to 2088) o0.0001
Unable to participate† 1.630 (2.488 to 0.950) – –
Side effects
None 0.633 (0.522 to 0.805) 1059 (1049 to 1084) o0.0001
Headache 4 days per month 0.101 (0.229 to 0.009) 36 (23 to 43) 0.0523
Nausea 4 days per month 0.126 (0.259 to 0.007) 405 (378 to 451) 0.0521
Stomach pain 4 days per month† 0.406 (0.571 to 0.269) – –
Drug treatment
Injection 4 days per month 0.134 (0.050 to 0.230) 175 (165 to 193) 0.0011
Pill 4 days per month 0.013 (0.084 to 0.116) 230 (229 to 268) 0.4647
IV infusion once per month† 0.146 (0.270 to 0.043) – –
Days missed from school*
Half day per month 0.022 (0.066 to 0.019) 32 (27 to 95) 0.0002
One day per month 0.045 (0.131 to 0.037) 65 (54 to 189)
Two days per month 0.090 (0.262 to 0.075) 129 (108 to 379)
Four days per month 0.179 (0.525 to 0.149) –
Cost to you (per month) ($)*
50 0.035 (0.046 to 0.026) – o0.0001
700 0.485 (0.642 to 0.360) –
1500 1.039 (1.375 to 0.771) –
2100 1.454 (1.925 to 1.079) –
Child age  Moderate pain 0.035 (0.003 to 0.069) 0.015
Years with JIA  Participation without any difﬁculty 0.147 (0.055 to 0.240) o0.0001
Child age  Participation without any difﬁculty 0.107 (0.172 to 0.046) o0.0001
Male  Participation without any difﬁculty 0.241 (0.558 to 0.054) 0.011
Biologic or DMARD  Participation with much difﬁculty 0.152 (0.027 to 0.348) 0.034
High income  Participation with much difﬁculty 0.227 (0.402 to 0.066) 0.001
Monthly spending  Participation with much difﬁculty 2.9  104 (4.1  104 to 0.001) 0.037
Public coverage  Cost to you 5.1  104 (8.5  105 to 0.001) 0.004
Low income  Cost to you 4.7  104 (7.1  104 to 0.002) 0.002
Mid income  Cost to you 0.001 (6.3  106 to 0.002) 0.002
Male  Days missed 0.145 (0.065 to 0.233) o0.0001
Notes. n ¼ 105  16. McFadden’s pseudo R2 ¼ 0.218.
CI, conﬁdence interval; DMARD, disease-modifying anti-rheumatic drugs; IV, intravenous; JIA, juvenile idiopathic arthritis; MWTP, marginal
willingness to pay.
* Continuous coding.
† Reference level.
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 8 3 0 – 8 3 7 833cases, parents’ MWTP for transitions between attribute levels
toward improvement represented a positive change in utility.
Table 3 presents parents’ MWTP. Parents were willing to pay the
most for the transition from participation with much difﬁculty to
participation with some difﬁculty, $1674 (95% CI $1180–$1807),
followed by the transition from severe to moderate pain, $1606
(95% CI $855–$2429). The elimination of side effects was assigned
the third highest value, with parents willing to pay $1059
(95% CI $1049–$1084) for the transition from a headache 4 days
per month to no side effects. Figure 1 provides a graphical
representation of how parents traded between levels within an
attribute.
The WTP for nonbiologic and biologic DMARDs was computed
using the base-case proﬁles deﬁned in Table 1. A sensitivityanalysis was carried out by varying the attribute levels used to
represent a child on nonbiologic therapy. Results from the WTP
proﬁle analysis are presented in Table 4. Using the base-case
proﬁles, it was found that parents were willing to pay $2080 (95%
CI $1226–$3276) more for a biologic agent administered once a
week at home by subcutaneous injection and $1644 (95% CI $670–
$2909) more for a biologic administered once a month in a
hospital clinic by IV infusion compared with a nonbiologic
DMARD administered orally once a week. When the nonbiologic
therapy was assumed to be equally effective as the biologic
therapies, parents expressed a negative MWTP, meaning they
were no longer willing to pay more for the biologic injection,
$148 (95% CI $504 to $236), or the IV biologic, $585 ($1060 to
$132).
Fig. 1 – The marginal WTP of each level relative to the reference level (most severe level) is depicted for each attribute,
including drug treatment, days missed from school, side effects, participation in daily activities, and child-reported pain from
arthritis. IV, intravenous; WTP, willingness to pay.
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 8 3 0 – 8 3 7834Discussion
Although children with JIA have beneﬁted greatly in the last
decade from the introduction of biologics, and with more agents
expected to enter the market in coming years, access may be
deterred by the high cost of these medications. A paucity of
evidence of cost-effectiveness limits a drug plan decision maker’s
ability to make allocation decisions, resulting in variation in
formulary approvals across jurisdictions. In Canada and many
parts of Europe, drug plan beneﬁts in public plans are decided at aTable 4 – Incremental WTP for treatment with a
biologic compared with a nonbiologic drug.
Scenario WTP (95% CI) (CAN $)
Biologic
injection
Biologic
intravenous
infusion
Base case 2080 (1226 to 3276) 1644 (670 to 2909)
Injection 1906 (1033 to 3112) 1469 (477 to 2744)
No side effects 985 (98 to 2103) 549 (458 to 1736)
Equal effectiveness* 148 (504 to 236) 585 (1060 to 132)
CI, conﬁdence interval; DMARD, disease-modifying anti-rheumatic
drug; WTP, willingness to pay.
* Sensitivity analysis wherein the value for the nonbiologic
DMARD scenario was set as equivalent to that of the biologic.provincial level, with geographically independent regions decid-
ing which drugs they will pay for and under which conditions
[13]. Individuals without private drug coverage must rely on
public plans or pay for drugs out of pocket.
Currently, lack of adequate coverage, high co-payments, and
cost sharing for biologics for JIA serve as impediments to use [7].
Thus, children with JIA may not be receiving optimal treatment.
This can have a profound effect on not only the patient but also
the patient’s family, the health care system, and society [34,37].
In the United States, drug plans vary greatly in terms of co-
payment schemes and listings, with many requiring large out-
of-pocket payments [38]. Recently, the US Affordable Care Act
and the US Institute of Medicine embraced the concept of value-
based insurance design [39]. Unlike coinsurance, which is
simply a constant percentage of price, co-payments in a value-
based insurance design framework reﬂect an evidence-based
approach that creates incentives for individual patients to use
the most effective or cost-effective therapies. [40]. Understand-
ing parents’ preferences and WTP for treatments in JIA is a key
piece of evidence to guide sound drug policy decision making.
The present study found that parents of children with JIA
showed the greatest preference and were willing to pay more
for treatments that provided improvements to a child’s health
and quality of life. Attributes related to treatment effectiveness,
speciﬁcally pain relief and improved participation in daily
activities, were most valued by parents, followed by the elimi-
nation of side effects of treatment. These ﬁndings are consistent
with other preference-based studies in adults with rheumatoid
arthritis that measured the relative importance of treatment
effectiveness over other outcomes such as safety, convenience,
and cost [41,42]. The present study also demonstrated a greater
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ience and safety.
Parents were willing to pay between $1644 and $2080 more per
month for biologic treatments if adequate response could not be
achieved with nonbiologic DMARDs. This is more than the
monthly cost of these medications and equates to approximately
30% of the average monthly income for a family earning $80,000
per year (study sample mean). In a contingent valuation study by
Barron et al. [43], parents of children with JIA’s WTP for a
treatment that guaranteed clinical remission was equal to 15%
of the average monthly family income. No other previously
published studies have evaluated the WTP for drug treatments
in JIA.
One of the methodological issues raised by this study relates
to the coding of the cost attribute and the precision of WTP
estimates. All WTP ﬁndings were based on the assumption that
the marginal utility of cost is linear and that each additional
dollar represented the same marginal effect on choice. When the
cost attribute, however, was modeled as a categorical variable,
each additional dollar did not represent the same marginal effect
on choice and parents showed a slightly stronger preference to
move from $700 to $1500 and a slightly lesser preference to move
from $50 to $700 or $1500 to $2100 (see Fig. 2). This suggests that
monetary values between $700 and $1500 had a greater impact on
preference for treatments than did higher or lower values. This
ﬁnding highlights not only the impact that statistical approaches
can have on WTP ﬁndings but also the importance of selecting
appropriate ranges and intervals between the levels used to
represent cost [25,44].Fig. 2 – The marginal utility of money when “cost to you”
was coded as a categorical variable. (A) The slopes of the
lines represent the marginal utility of money when the
levels of cost to you were treated as categorical. (B) Values
for the slope of the line between 1) $50 and $700, 2) $700 and
$1500, and 3) $1500 and $2100 when the levels of cost to you
were treated as continuous or categorical. *Values derived
from the regression model when the attribute is coded as
categorical.Following a pilot study of the DCE, the upper level of the cost
attribute was increased from $1500 to $2100 to ensure that
respondents’ highest maximum WTP would be uncovered. All
the WTP values estimated in this study fell below $2100, suggest-
ing that the range of cost levels was appropriate. It is more
difﬁcult to conﬁrm whether parents overstated their WTP as a
result of hypothetical bias because the choice scenarios were
presented as hypothetical rather than actual treatment decisions
that parents face. Parents were not told that their responses
would affect drug prices or drug policy, and there was no
expectation that their responses would be used to inform policy
discussions. Respondents were told only that “this survey will
help us understand how you value drugs used to treat a child
with juvenile idiopathic arthritis.” Moreover, a cheap talk script
was used to mitigate the potential for hypothetical bias. The
wording in the preamble was designed to be incentive-
compatible by asking respondents to carefully consider cost and
respond as if they would actually have to pay the extra amount
each month. The proportion of respondents who selected each
level of the cost to you attribute was examined. It was deter-
mined that 23% of the responses were for the highest level
($2100), 24% were for $1500, 24% were for $700, and 28% were
for the lowest level of $50. The stability of the proportions from
level to level at the higher levels of this attribute suggests that
there was no hypothetical bias causing respondents to choose
the highest level more often than other levels of “cost to you”.
Although stated preference WTP is useful for priority setting
in situations in which efﬁcient markets for health care goods do
not exist, future research on methods to further mitigate hypo-
thetical bias is necessary.
The present DCE presented paired scenarios with no opt-out
or status quo options. Such options are usually required to derive
theoretically reliable estimates of WTP unless the presence of an
opt-out option fails to mimic the “real market situation” [45].
Following pilot testing of the survey instrument, it was decided
that an opt-out option would not be realistic to parents of
children with JIA because treatment is required to prevent
long-term irreversible damage. A status quo was also not
included because the pairwise choice tasks included levels that
represented the status quo (e.g., treatment attributes included
levels reﬂecting methotrexate use and allowed for a full spec-
trum of improvement or worsening in terms of health out-
comes). Thus, a range of attribute levels reﬂecting the cost of
treatment under different health state scenarios was included in
the experimental design and utility was estimated for different
states and varying conﬁgurations of states over 16 choice tasks
for each respondent. Furthermore, given the inclusion of 16
choice tasks and a series of health and demographics questions
in each questionnaire, adding an opt-out option to each choice
task would increase task complexity and potentially decrease
respondent efﬁciency. Another concern is that including an opt-
out option decreases statistical efﬁciency because nothing new is
learned about trade-offs between attribute levels when respond-
ents opt out and information about preferences or the reason for
opting out is not acquired. Therefore, unless researchers fully
understand what status quo and opt-out options mean to
respondents, it is not always useful to include them [46,47]. In
the absence of opt-out or status quo options, the coefﬁcients must
be interpreted as being relative in the context of a discrete choice
between two treatment options. It is unknown to what extent
estimates for MWTP would change in the presence of opt-out or
status quo choice options. Parameter uncertainty in the MWTP
estimates is reﬂected in the CIs reported alongside the point
estimates.
Many parents may not encounter a monthly payment of
$2100 for JIA treatments. It has been shown that when a study
subject is unaccustomed to evaluating costs as high as those
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 8 3 0 – 8 3 7836presented in a DCE, he or she sometimes uses simplifying
strategies to help him or her make trade-offs [48]. Some of these
strategies may include ignoring cost altogether, lowering indi-
cated costs to a value that they are accustomed to paying, or
recalibrating the costs using heuristics such as “low,” “medium,”
or “high” regardless of their actual values [48,49]. In this study,
cost was assigned a high relative importance compared with
other attributes, suggesting that most parents were in fact
considering the speciﬁed cost when choosing a treatment,
although there is no practical way to determine whether sim-
plifying tactics were used. There is also no practical way to
determine whether respondents accepted the levels of cost as
income-constrained, out-of-pocket monthly expenses required
to obtain the most preferred treatment. The ﬁnding that parents
from low- and middle-income households demonstrated a lower
maximum WTP for drug treatments than did parents from high-
income households suggests that respondents were considering
the choices as realistic decisions. Parents were offered the ability
to rate their level of uncertainty for each choice task. A separate
analysis explored the link between task complexity and statis-
tical precision in WTP estimates as a function of the level of
certainty expressed by respondents when completing choice
tasks. That analysis found that more complex tasks decreased
response certainty and adjusting the regression to favor
respondents who are more uncertain (i.e., who deliberated more
on the choice) increased the statistical precision of the econo-
metric model [50].
The present sample may have represented a higher socio-
economic status than that of the general population, with 60%
reporting annual household incomes of more than $80,000, while
the mean household income for a two-parent family with
children in Canada was $114,000 in 2011 [51]. Although this
may have caused more respondents to choose higher levels of
WTP, as described above, monetary values between $700 and
$1500 had a greater impact on preference than did higher or
lower values. The model was adjusted for income effects by
including a Household income  Cost to you interaction term. It
remains unknown whether differences in health care systems
between countries would inﬂuence parents’ relative preferences
for attributes related to the safety, effectiveness, and cost of
treatments for JIA. Interpretation and generalizability of WTP
estimates is limited by the extent that populations of other
jurisdictions resemble the characteristics of the present sample,
including drug plan coverage and cost sharing.Conclusions
This assessment of parents’ preferences showed that parents
were willing to pay more than the monthly price of biologic
medications although these are expensive. Private and public
funding programs need to explore ways by which coverage of and
access to biologics, considered the standard of care for many
children with JIA [6], can be improved [9–11]. The present study
contributes valuable evidence for drug plan decision makers in
North America. Further research examining the preferences of
health care practitioners and children would be beneﬁcial. Stud-
ies assessing how drug plan decision makers use evidence for
coverage decisions in chronic childhood conditions are also
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